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Visfatin has recently been identified as a novel visceral adipokine which may be involved in obesity-related vascular disorders. However, it is
not known whether visfatin directly contributes to endothelial dysfunction. Here, we investigated the effect of visfatin on vascular inflammation, a
key step in a variety of vascular diseases. Visfatin induced leukocyte adhesion to endothelial cells and the aortic endothelium by induction of the
cell adhesion molecules, ICAM-1 and VCAM-1. Promoter analysis revealed that visfatin-mediated induction of CAMs is mainly regulated by
nuclear factor-κB (NF-κB). Visfatin stimulated IκBα phosphorylation, nuclear translocation of the p65 subunit of NF-κB, and NF-κB DNA
binding activity in HMECs. Furthermore, visfatin increased ROS generation, and visfatin-induced CAMs expression and NF-κB activation were
abrogated in the presence of the direct scavenger of ROS. Taken together, our results demonstrate that visfatin is a vascular inflammatory molecule
that increases expression of the inflammatory CAMs, ICAM-1 and VCAM-1, through ROS-dependent NF-κB activation in endothelial cells.
© 2008 Elsevier B.V. All rights reserved.Keywords: Cell adhesion molecules; NF-κB; Reactive oxygen species; Vascular inflammation; Visfatin1. Introduction
The inflammatory reaction involves complex interactions be-
tween inflammatory cells (neutrophils, lymphocytes, and mono-
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doi:10.1016/j.bbamcr.2008.01.004smooth muscle cells). Vascular cells regulate the inflammatory
process through the expression of adhesionmolecules, cytokines,
chemokines, and growth factors [1–3]. Endothelial cell adhesion
molecules (ECAMs), such as E-selectin, VCAM-1, and ICAM-1,
are up-regulated in the vascular endothelium in response to
inflammatory stimuli, which in turn mediates leukocyte recruit-
ment and adherence to the endothelium at the early stages of
vascular inflammation, ultimately leading to the progression of
numerous vascular diseases [4].
Adipose tissue is a dynamic paracrine and endocrine organ
that secretes several hormones and cytokines (termed “adipo-
kines”). These adipokines function in the pathogenesis of the
insulin resistance syndrome, and directly affect vascular function
[5]. Adipokines such as resistin and leptin are proinflammatory
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atherogenesis [6,7].
Visfatin (also known as pre-B-cell colony-enhancing factor,
PBEF) is a novel adipokine that is preferentially produced by
visceral adipose tissue and has insulin-mimetic actions [8]. It
also functions as a proinflammatory adipocytokine that is sec-
reted by neutrophils in response to inflammatory stimuli and up-
regulates the production of cytokines in the monocytes [9,10],
suggesting a potential role in the pathogenesis of inflammatory
disorders. We have previously reported that visfatin promotes
angiogenesis [11] which can be associated with obesity-related
vascular diseases, including atherosclerosis, diabetes, and hy-
pertension [12,13].
In this study, we hypothesized that visfatin directly promotes
endothelial dysfunction. Visfatin markedly increased the ex-
pression of ICAM-1 and VCAM-1, which bind leukocytes to
endothelial cells through the activation of NF-κB, via the ROS
production in endothelial cells.2. Materials and methods
2.1. Reagents and recombinant proteins
N-acetyl-L-cysteine (NAC), oxypurinol, rotenone, diphenylene iodonium
(DPI), pyrrolidine dithiocarbamate (PDTC), polymyxin B, and dihydroethidium
(DHE) were obtained from Sigma. Calcein-AM was obtained from Molecular
Probes. Mouse monoclonal anti-ICAM-1, mouse monoclonal anti-VCAM-1,
rabbit polyclonal anti-NF-κB p65, mouse monoclonal anti-IκBα, and rabbit
monoclonal anti-phospho-IκBα antibodies were obtained from Santa Cruz Bio-
technology. Human α-tubulin antibody was purchased from Biogenex. FITC-
conjugated donkey anti-rabbit IgGwas purchased from Jackson Immunoresearch.
The full-length human visfatin expression vector was constructed by PCR and
subcloned into the pET vector (Novagen). For production of His fusion protein,
pET-visfatin was transformed and His-visfatin protein was purified on the Talon
metal affinity column (CLONTECH). This protein was dialyzed using the
Sephadex G-25 column (Amersham Pharmacia Biotech). The eluted protein was
desalted using a PD-10 Desalting column (Amersham Pharmacia Biotech) into
phosphate-buffered saline (PBS). The endotoxin level in the recombinant visfatin
was below 0.05 EU (b5 pg/ml) as determined by Limulus amebocyte lysate
testing (Associates of Cape Cod, Inc.). The amount of LPS present in our visfatin
preparationwas below5 pg/ml, whereas the critical amount to induce ICAM-1 and
VCAM-1 gene expression in endothelial cells exceeded 100 pg/ml [14,15].
2.2. Cell culture
Human microvascular endothelial cells (HMECs) were obtained from the
CDC (Atlanta, GA). These cells were maintained in MCDB supplemented with
10% FBS (Invitrogen), 1% antibiotics, 1 μg/ml hydrocortisone, and 10 ng/ml
hEGF at 37 °C under a humidified 95% to 5% (vol/vol) mixture of air and CO2.
Primary human umbilical vein endothelial cells (HUVECs) (passage 5–8) were
purchase from CLONECTICS. The HUVECs were plated onto 0.3% gelatin-
coated dish and grown in M199 (Invitrogen) with heat-inactivated 20% FBS
(Invitrogen), 3 ng/ml bFGF, and 100 μg/ml heparin. U937 monocytic cells were
grown in RPMI-1640 (Invitrogen) with 10% FBS (Invitrogen) and 1%
antibiotics.
2.3. In vitro monocyte adhesion assay
HMECswere plated on 24well plates at 5×104 cells/well and incubatedwith or
without visfatin for 8 h. U937 cells were then added (5×105 cells/ml, 200 μl/well)
to the confluent monolayers of HMECs and incubated for 30 min. Non-adherent
monocytes were removed by washing twice with PBS. Adherent cells were fixed
and washed twice with PBS. Binding of monocytes to the endothelial cells werestainedwithDiff-Quick (Sysmex), and the adherent cells were counted in 3 separate
fields in each well by microscopy (Nikon). The average number of adherent
monocytes was calculated in the three fields for each set of four wells.
2.4. Ex vivo monocyte adhesion assay
The ex vivo binding of monocytes to the aorta dissected from rats was examined
by ex vivo monocyte binding assay [16]. Male Sprague–Dawley rats (SD, 6 weeks
of age), weighing 210–230 g,were obtained fromSamtako,Osan,Korea. All animal
studies were conducted in accordance with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 85-23 revised 1996). The aortas were
opened longitudinally, and incubated with visfatin for 16 h. The aortas were then
incubated for 30 min with 1×106 fluorescence-labeled (using Calcein-AM) mono-
cytes. After incubation, unbound monocytes were rinsed away; the adherent mono-
cytes were counted in 3 consistent fields using fluorescence microscopy (Nikon).
2.5. In vivo assessment of macrophage adhesion and infiltration in vivo
Peritoneal macrophage was isolated with intraperitoneal stimulation of 4%
triglycolate for four days. The macrophages were plated after washing them with
RPMI twice. After 15 h, floating cells were removed and the attached macro-
phages were labeled with Cell tracker-Red (Molecular Probes) according to the
manufacturer's instruction. The labeled cells (5×104) were administrated to a
tail vein and fluorescence imaging was noninvasively performed through the
mouse ear where 10 μl of visfatin (1 mg/ml) or saline was subcutaneously
delivered 15 h before the imaging acquisition. Vasculature was episcopically
visualized under a fluorescence intravital microscope.
2.6. RT-PCR
Total RNAwas isolated from HMECs with a TRIzol reagent kit (Invitrogen).
cDNA synthesis was performed on 3 μg of total RNAwith a reverse transcrip-
tion kit (Promega). The oligonucleotide primers for PCR were designed as
follows: β-actin, 5′-GACTACCTCATGAAGATC-3′ and 5′-GATCCACAT-
CTGCTGGAA-3′; ICAM-1, 5′-CGATGACCATCTACAGCTTTCCGG-3′ and
5′-GCTGCTACCACAGTGATGATGACAA-3′; VCAM-1, 5′-GATACAACC-
GTCTTGGTCAGCCC-3′ and 5′-CAGTTGAAGGATGCGGGAGTATATG-3′.
2.7. Real-time PCR
Real-time PCR quantification was performed using a SYBR Green approach
(Light Cycler; Roche Applied Science, Penzberg, Germany). Cycling param-
eters consisted of 1 cycle of 95 °C for 10 min, followed by amplification for
30 cycles of 95 °C for 10 s, 57 °C for 5 s, and 72 °C for 7 s. Subsequently, a
melting curve program was applied with continuous fluorescence measurement.
The entire cycling process including data analysis took less than 1 h and was
monitored using the LightCycler® software program (version 4.0).
2.8. Western immunoblot analysis
Harvested cells were lysed in a lysis buffer (40 mM Tris–Cl, 10 mM EDTA,
120 mM NaCl and 0.1% NP-40 with protease inhibitor cocktail (Sigma)). A
constant protein concentration (30 μg/lane) was used. Proteins were separated by
SDS/PAGE and transferred to a nitrocellulose membrane (Amersham Pharmacia
Biotech). Themembrane was blockedwith 5% skimmilk in PBS containing 0.1%
Tween-20 for 1 h at room temperature and probed with appropriate antibodies.
This signal was developedwith the enhanced chemiluminescence (ECL) detection
system (Amersham Pharmacia Biotech).
2.9. Immunocytochemistry
Cells cultured on a coverglass were fixed in 4% paraformaldehyde for
10 min, blocked with 0.5% Triton X-100/PBS for 5 min, and then labeled with
the appropriate primary antibodies and FITC-conjugated secondary antibody.
Coverslips were mounted in Vectastain containing DAPI (Vector Laboratories).
Cells were analyzed using fluorescence microscopy (Nikon).
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Cells were plated on 24-well plates and transfected with the luciferase construct
and pCMV-β-gal using Lipofectamine plus reagents (Invitrogen). Cell extracts were
prepared 48 h after transfection, and then analyzedwith theβ-galactosidase enzyme
assay for luciferase activity using an assay kit (Promega) and a luminometer (Tuner
Biosystems). Each extract was assayed at least three times and relative luciferase
activity was calculated as RLU/β-galactosidase. ICAM-1 and VCAM-1 luciferase
reporter constructs with full-length (ICAM-1: −1350 to +45 bp, VCAM-1: −1716
to +119 bp) and truncated forms (ICAM-1: −485 to +45 bp, VCAM-1: −213 to
+119 bp) were used as previously reported [17].
2.11. Nuclear extraction and EMSA
Nuclear extracts from HMECs were prepared and analyzed by EMSA as
previously described [18]. Binding reactions containing equal amounts of protein
(10 μg) and 20 fmol of biotin-labeled NF-κB oligonucleotide (probe) were
performed for 20 min in binding buffer (10 mM Tris–Cl, 50 mM KCl, 5 mM
MgCl2, 1 mM DTT, 0.05% NP-40, 1 μg poly (dI·dC) and 2.5% glycerol).
Binding reactionswere analyzed using 6%native PAGE.After blotting to a nylonFig. 1. Visfatin stimulates leukocytes adhesion to endothelial cells in vitro and in
followed by measuring the adhesion of U937 monocytes as described in “Material
B, Adhesion of fluorescence-labeled monocytes to the endothelium of rat aorta. Cal
magnification. Data is the mean±SE relative to adhesion of untreated cells (set at 100
and infiltration was performed at 2 h after administration of the labeled macropha
infiltration (arrowhead) compared with the vehicle-treated group where the basal leve
in fields of views (250×350 μm2) of nine images were counted and summarized. ⁎membrane, labeled oligonucleotides were detected with the LightShift Chemi-
luminescent EMSA Kit following the instructions of the manufacturer (Pierce).
2.12. Determination of intracellular ROS
Intracellular ROS were detected in cultures using the oxidant-sensitive
fluorogenic probe dihydroethidium (DHE), as previously described [19]. After
loadingwithDHE (10μM) for 30min at 37 °C, cultureswere treatedwith visfatin
for 20 min. After these treatments, cultures were washed once with PBS, and
ethidium-positive cells were detected using a fluorescence microscope (Nikon)
equipped with a digital camera.
2.13. Measurement of NAD(P)H oxidase activity
NAD(P)H oxidase activity was measured with the lucigenin assay which is
specific for superoxide. Cells were homogenized with a lysis buffer containing
protease inhibitor (20 mMmonobasic potassium phosphate, pH 7, 1 mMEGTA).
NAD(P)H oxidase was determined in a 50 mM phosphate buffer, pH 7.0,
containing 1 mM EGTA, 150 mM sucrose, 5 μM lucigenin as the electron
acceptor, and 100 μM NAD(P)H as the substrate [20]. The reaction was startedvivo. A, HMECs were incubated with or without visfatin (500 ng/ml) for 8 h,
s and methods”. Arrows indicate the adhesion of U937 monocytes to HMECs.
cein-AM stained monocytes were identified by fluorescence microscopy at 40×
%) in triplicate experiments. C, Imaging assessment of the macrophage adhesion
ge. The visfatin-treated area of the mouse ear showed increased adhesion and
l of adhesion (arrow) was observed (scale bar=50 μm). The macrophage staying
Pb0.01; ⁎⁎Pb0.05 compared to control.
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luminometer (Turner Biosystems).
3. Results
3.1. Visfatin induces adhesion of leukocytes to endothelial cells
in vitro and in vivo
We first investigated the effect of visfatin on the adhesion of
leukocytes to endothelial cells, a critical step in vascular
inflammation [4]. Treatment with visfatin (500 ng/ml) for 8 h
enhanced the adhesiveness of U937 cells to HMECs (Fig. 1A)
and HUVECs (Fig. S1). This dose of visfatin has been widely
used to investigate the in vitro proinflammatory effects of
visfatin in various cultured cells [9,21,22]. To determine
whether visfatin induced monocyte binding to the ex vivo aorta,
we performed an ex vivo adhesion assay using fluorescence-
labeled monocytes and an aorta isolated from an SD rat.
Fluorescent cells were observed on the surface of the aortic
endothelium (Fig. 1B), and visfatin treatment increased the
number of adherent cells by three times versus the control
aorta. Next, to examine the effect of visfatin on macrophage
adhesion in vivo, we introduced a noninvasive imaging system
using an in vivo vital microscope as described in “Materials
and methods”. As shown in Fig. 1C, visfatin-treated mice
showed a significant increase of macrophage adherence or
infiltration to the blood vessels compared with vehicle-treated
mice.Fig. 2. Visfatin induces mRNA and protein expression of ICAM-1 and VCAM-1 in HM
24 h (B). A, Total RNAswere isolated and then analyzed by RT-PCR using specific pri
Using real-time RT-PCR, we also quantified the expression levels of ICAM-1 and VC
The expression level of control (untreated) was set to 1, and the values are normalized
VCAM-1 protein levels were examined by Western blotting using anti-ICAM-1 and3.2. Visfatin increases ICAM-1 and VCAM-1 expression in
endothelial cells
Cell adhesion molecules, such as ICAM-1 and VCAM-1, on
endothelial cells mediate leukocyte adhesion to the endothelium
during inflammation [1–3]. Therefore, we investigated whether
visfatin could induce the expression of ICAM-1 and VCAM-1
on endothelial cells. Treatment of HMECs with visfatin in-
creased the expression of ICAM-1 and VCAM-1 mRNA and
the protein levels in a dose-dependent manner (Fig. 2A, left
and B). Using real-time RT-PCR, we also quantified the expres-
sion levels of ICAM-1 and VCAM-1 mRNA enhanced by vis-
fatin in the presence of 10 μg/ml endotoxin-neutralizing agent
polymyxin B (Fig. 2A, right).
3.3. Visfatin induces the promoter activity of ICAM-1 and
VCAM-1 genes through NF-κB
NF-κB is a potent proinflammatory nuclear transcription
factor, and activation of NF-κB is a central event in the initiation
and amplification of inflammatory responses [23]. Both ICAM-1
and VCAM-1 promoters contain NF-κB binding sites. The prox-
imal NF-κB binding sites located ∼200 bp (ICAM-1), and 65
and 75 bp (VCAM-1) upstream of the transcription start site are
particularly important for the induction of ICAM-1 andVCAM-1
transcription [17,24]. To determine if NF-κB was involved in
visfatin-mediated increases in ICAM-1 and VCAM-1, we trans-
fected ICAM-1 and VCAM-1 luciferase reporter constructs, bothECs. HMECs were incubated with or without visfatin (500 ng/ml) for 4 h (A) or
mers to human ICAM-1 and VCAM-1.β-actin served as an internal control (left).
AM-1 mRNA. Culture medium was supplemented with 10 μg/ml polymyxin B.
to β-actin mRNA levels (right). ⁎Pb0.01 compared to control. B, ICAM-1 and
anti-VCAM-1 antibodies. α-tubulin served as the loading control.
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promoter regions of both adhesion molecules have several tran-
scription factor binding sites, including NF-κB, ARE, and TATA
for the 1.4 kb ICAM-1 promoter, and NF-κB, TRE, and GATA
for the 1.8 kb VCAM-1 promoter (Fig. 3). Both the ICAM-1 and
VCAM-1 truncated forms contain proximal NF-κB binding sites
(Fig. 3). Visfatin significantly increased promoter activity in the
truncated ICAM-1 and VCAM-1 promoters, which shows simi-
lar increase in the reporter activities of full-length ICAM-1 and
VCAM-1 genes (Fig. 3A and B), indicating that NF-κB binding
sites are essential and sufficient for the visfatin-induced tran-
scriptional activation of ICAM-1 and VCAM-1 genes. Further-
more, pyrrolidine dithiocarbamate (PDTC), a potent inhibitor of
NF-κB [25], reduced visfatin-induced ICAM-1 and VCAM-1
mRNA levels (Fig. 3C). Thus, the NF-κB binding site is directly
involved in the visfatin-mediated activation of the ICAM-1 and
VCAM-1 promoter.Fig. 3. Visfatin increases the promoter activities of ICAM-1 and VCAM-1 genes th
(containingNF-κBmotif) promoter of ICAM-1 (A) andVCAM-1 (B) genes. HMECsw
into HMECs and incubated with or without visfatin (100 ng/ml) for 6 h. Data is the m
cells (set at 100%). ⁎Pb0.01 compared to untreated. C, HMECswere incubatedwith o
Total mRNAs were isolated, and RT-PCR analysis was performed using specific prim3.4. Visfatin stimulates NF-κB activation in endothelial cells
The main activated form of NF-κB is a heterodimer of the
p65 subunit (also called relA) associated with either a p50 or
p52 subunit. IκBα regulates transient NF-κB activation through
phosphorylation, ubiquitination, and proteolytic degradation of
IκBα [26]. Therefore, we examined the effect of visfatin on
IκBα phosphorylation and degradation using Western blot
analysis with antibodies against phosphospecific IκBα (Ser-32)
and IκBα. Visfatin induced phosphorylation of Ser-32 in IκBα,
with a maximal effect after 20 min of visfatin stimulation (Fig.
4A). Some degradation of IκBα was observed at 30 min in
HMECs (Fig. 4B). Visfatin also significantly increased the
nuclear translocation of the p65 subunit of NF-κB (Fig. 4C).
Nuclear extracts were prepared and subjected to an EMSAwith
a specific probe for the NF-κB binding site. As expected,
visfatin stimulated the binding of nuclear extracts to the NF-κBrough NF-κB. A, B, Top, schematic representation of full-length and truncated
ere transiently transfectedwith ICAM-1 (A) andVCAM-1 (B) luciferase vectors
ean±SE of triplicate experiments relative to the luciferase light units in untreated
r without visfatin (500 ng/ml) in the presence or absence of 100 μMPDTC for 4 h.
ers to human ICAM-1 and VCAM-1. β-actin served as an internal control.
Fig. 4. Visfatin induces IκBα phosphorylation, NF-κB nuclear translocation, and NF-κB DNA binding activity. A, B, HMECs were incubated with or without visfatin
(500 ng/ml) for the indicated times. Western blots were probed with anti-phospho-IκBα (A) and anti-IκBα (B) antibodies. α-tubulin served as the loading control.
⁎⁎Pb0.05 compared to untreated. C, HMECs was incubated with or without visfatin (500 ng/ml) for 30 min and subjected to immunocytochemical analysis of p65
localization as described in “Materials and methods”. Cells were stained with NF-κB p65 (green) and nuclei were revealed with DAPI (blue). Bar=20 μm. D, NF-κB
binding activities in nuclear extracts were measured by EMSA. HMECs were incubated with visfatin (500 ng/ml, lanes 2, 3 and 4) for 30 min. Nuclear extracts from
these cells were incubated with biotin-labeled VCAM-1 NF-κB oligonucleotide. In the competition assay, 50× (lane 3) and 100× (lane 4) excess unlabeled probe were
added to the reaction mixtures.
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abrogated by addition of excess unlabeled NF-κB consensus
oligodeoxynucleotide (Fig. 4D, lanes 3 and 4). Thus, visfatin
promotes NF-κB activation in endothelial cells.
3.5. Visfatin-induced CAM expression and NF-κB activation
are associated with ROS production: involvement of NAD(P)H
oxidase
Reactive oxygen species (ROS) produced by cytokines,
growth factors, and vasoactive agents contribute to the
intracellular signaling cascades associated with inflammatory
responses [27,28]. ROS induce NF-κB activation by modifying
the activity of one or more of the kinase enzymes in the NF-κB
activation cascades [29]. Therefore, we investigated whether
visfatin could induce ROS generation in HMECs. The
fluorogenic probe, dihydroethidium (DHE), was used to assess
the effect of visfatin on ROS generation. Also the thiol reducing
agent N-acetyl-L-cysteine (NAC) is known as a direct scavenger
of ROS and commonly used in studies to establish the role of
ROS in gene expression [30]. As shown in Fig. 5A, visfatin
significantly increased ROS generation, and visfatin-induced
DHE fluorescence was abolished in the presence of NAC. We
then examined the effect of NAC on the visfatin-induced
ICAM-1 and VCAM-1 gene expression. The pretreatment of
HMECs with NAC inhibited visfatin-induced ICAM-1 and
VCAM-1 mRNA expression (Fig. 5B). We further investigated
whether NAC down-regulates visfatin-induced NF-κB activa-
tion, leading to the decrease in the expression of ICAM-1 and
VCAM-1. NAC also significantly suppressed visfatin-induced
phosphorylation of IκBα in HMECs (Fig. 5C) and visfatin-
induced NF-κB binding activity (Fig. 5D). Thus, visfatin
mediates NF-κB activation and CAMs induction via ROS-
dependent mechanism. And to determine the main enzymatic
source of visfatin-induced ROS, we pretreated HMECs with
inhibitors of different enzymatic sources of ROS. Pretreatment
of HMECs with NAD(P)H oxidase inhibitor (DPI) significantly
inhibited visfatin-induced increases in ICAM-1 and VCAM-1
mRNA expression (Fig. 5E). And NAD(P)H oxidase activity
was examined by the measurement of lucigenin chemi-
luminescence. As shown in Fig. 5F, visfatin increased NAD(P)
H oxidase activity, which was blocked by DPI, indicating that
visfatin-induced ROS production occurs, at least in part, through
NAD(P)H oxidase activation.Fig. 5. Involvement of ROS in visfatin-induced ICAM-1 and VCAM-1 expression an
in the presence or absence of inhibitors for 30 min (A, C, D and F) and 4 h (B and E).
“Materials and methods”. Bar=100 μm. Data are mean±SE of triplicate experiments
compared to control; #Pb0.01 compared to visfatin. B, HMECs were pretreated with
by RT-PCR using specific primers to human ICAM-1 and VCAM-1. β-actin serve
expression levels of ICAM-1 and VCAM-1 mRNA. Culture medium was supplemen
set to 1, and the values are normalized to β-actin mRNA levels (right). ⁎Pb0.01 compa
without NAC (5 mM) for 30 min.Western blots were probed with anti-phospho-IκBα
for NF-κB binding activities by EMSA. Culture medium was supplemented with 10
oxidase inhibitor, DPI (10 μM), the xanthine oxidase inhibitor, Oxypurinol (10 μM
30 min. Total mRNAs were isolated, and RT-PCR analysis was performed using sp
control. F, HMECs were pretreated with or without DPI (10 μM) for 30 min and th
phosphate buffer containing NAD(P)H as a substrate. ⁎⁎Pb0.05 compared to contr4. Discussion
In the present study, we demonstrated that visfatin induces
ICAM-1 and VCAM-1 expression through ROS-dependent
NF-κB activation in HMECs on the basis of the following
evidence: (1) Visfatin induced adhesion of leukocytes to endo-
thelial cells in vitro and in vivo, which correlated with ICAM-1
and VCAM-1 induction; (2) Visfatin-induced CAM expression
required the activation of NF-κB; and (3) ROS were responsible
for both visfatin-induced ICAM-1 and VCAM-1 expression and
visfatin-stimulated activation of NF-κB.
Obesity, characterized by an excess accumulation of body fat,
is a significant risk factor for cardiovascular diseases such as
atherosclerosis and hypertension [31,32]. Atherosclerosis is an
inflammatory process that begins with systemic endothelial dys-
function, a pivotal event in the early pathogenesis of athero-
sclerotic lesion formation [4,33]. The molecular mechanisms
linking obesity and atherosclerosis have yet to be fully eluci-
dated, but seem to involve fat-derived adipokines affecting en-
dothelial function and vascular homeostasis [7].
Adipokines such as leptin and resistin regulate the endo-
thelial expression of cell adhesion molecules and chemoattrac-
tant chemokines, one of the early important steps in
atherosclerosis [34,35]. These also serve as the cellular mediator
of endothelial dysfunction and metabolic syndrome of insulin
resistance, which exerts proatherogenic effects such as lipid
abnormalities, platelet aggregation and hypertension. In parti-
cular, leptin augmented thrombus and atheroma formation by
promoting vascular inflammation, arterial hypertension,
endothelial free radical overproduction, and cholesterol accu-
mulation under hyperglycemia [36–39]. Recently, it has been
reported that the expression of visfatin is high at plaque rupture
sites in patients with coronary artery disease [22]. We showed
that visfatin accelerates monocyte adhesion to endothelial cells
by up-regulating adhesion molecules in vascular endothelial
cells (Figs. 1 and 2), suggesting a possible role for visfatin in the
development of atherosclerosis. Of course, further studies are
necessary to clarify the atherogenic effect of visfatin and its
underlying molecular mechanism in the obesity-linked insulin
resistance, diabetes, and atherosclerosis.
The NF-κB transcription factor plays a significant role in
regulating proinflammatory genes in response to inflammatory
stimuli [40,41]. Kinases in the PI3K/Akt and MAPK cascades
regulate the NF-κB-dependent pathway [42,43]. In this study,d NF-κB activation. HMECs were incubated with or without visfatin (500 ng/ml)
A, ROS levels were detected using the fluorogenic probe DHE as detailed in the
relative to the DHE fluorescence units in untreated cells (set at 100%). ⁎Pb0.01
or without NAC (5 mM) for 30 min. Total RNAs were isolated and then analyzed
d as an internal control (left). Using real-time RT-PCR, we also quantified the
ted with 10 μg/ml polymyxin B. The expression level of control (untreated) was
red to control; #Pb0.01 compared to visfatin. C, HMECs were pretreated with or
antibodies. α-tubulin served as loading control. D, Nuclear extracts were assayed
μg/ml polymyxin B. E, HMECs were pretreated with or without the NAD(P)H
), or the mitochondrial NADH dehydrogenase inhibitor, rotenone (2 μM) for
ecific primers to human ICAM-1 and VCAM-1. β-actin served as an internal
en NAD(P)H oxidase activity was measured by luminescence assay in 50 nM
ol; #Pb0.01 compared to visfatin.
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in turn mediates NF-κB-dependent expression of the endothelial
cell adhesionmolecules, ICAM-1 andVCAM-1 (Fig. 4). Indeed,
visfatin up-regulates cytokine production via the p38MAPK
pathway and NF-κB p65 (RelA) DNA binding activity in human
leukocytes [9]. We previously showed that visfatin stimulates
extracellular signal regulated kinases 1/2 (ERK1/2) and slightlyactivates Akt in endothelial cells [11]. On the basis of these
findings, visfatin may up-regulate NF-κB activity via activation
of signal cascades such as MAPK and PI3K/Akt pathway.
However, we cannot exclude the possibility that visfatin may
work secondary to the release of other inflammatory cytokines
or proteins from endothelial cells, resulting in NF-κB activation.
These possibilities are currently under investigation.
894 S.-R. Kim et al. / Biochimica et Biophysica Acta 1783 (2008) 886–895Visfatin binds to and activates the insulin receptor via a
distinct binding site from insulin, which stimulates glucose up-
take in adipocytes [8]. In addition to the regulation of glucose
homeostasis, visfatin modulates immunomodulatory and inflam-
matory processes [9,10]. Visfatin also increases cytokine levels
in monocytes, whereas insulin does not, suggesting the presence
of an unidentified visfatin receptor [9,44]. In our preliminary
study, we checked whether the up-regulation of CAMs induced
by visfatin is dependent on insulin receptor activation. Thus, we
treated HMECs with HNMPA-(AM)3 (hydroxy-2-naphthalenyl-
methylphosphonic acid tris-acetoxy-methyl ester), a specific
inhibitor of insulin receptor tyrosine kinase [45]. HNMPA-(AM)3
had little effect on visfatin-stimulated ICAM-1 and VCAM-1
mRNA levels and visfatin-induced NF-κBDNA binding activity
(data not shown). Although further studies are needed, these
results suggest that the effects of visfatin on CAMs expression
may be mediated by its own unidentified receptor.
Oxidative stress is an important determinant of endothelial
dysfunction and vascular injury [46]. ROS influence a number
of cellular responses by turning on several intracellular sig-
naling cascades in vascular cells, which contribute to altered
vascular tone, vascular inflammation, and vascular remodeling,
thus leading to the progression of vascular diseases [47]. We
also showed that visfatin stimulates ROS generation in endo-
thelial cells, and antioxidants blocked visfatin-induced NF-κB
activation and CAM expression (Fig. 5). Based on these obser-
vations, visfatin may be able to accelerate obesity-related vascu-
lar diseases through ROS overproduction by inducing vascular
damage. NAD(P)H oxidase is a major source of ROS generation
in vascular endothelial cells, and critical in the regulation of
oxidative stress in the vasculature [48]. Dysregulated NAD(P)H
oxidase activity is associated with marked endothelial dysfunc-
tion in various states of vascular diseases [49]. We showed that
visfatin-induced CAM expression is significantly regulated by
NAD(P)H oxidase inhibitor, and visfatin enhances NAD(P)H-
dependent ROS production in endothelial cells. Of course, future
studies will be needed to determine the exact molecular mecha-
nisms underlying visfatin-induced endothelial NAD(P)H oxi-
dase activation and the potential roles of endothelial NAD(P)H
oxidase in obesity-related vascular dysfunction.
Precise understanding of pathophysiology and molecular
actions of visfatin will lead to the discovery of effective
therapeutic intervention. Development of pharmacological
visfatin antagonists and novel manipulations which inhibit
visfatin signaling may be promising strategies to attenuate the
proinflammatory effects of visfatin on endothelial cells and
ultimately to reduce the progression of obesity-related vascular
diseases.
In conclusion, the present study demonstrated for the first
time that a novel visceral adipokine, visfatin, has direct proin-
flammatory effects on vascular endothelial cells, which promote
the expression of endothelial cell adhesion molecules through
ROS-dependent NF-κB activation. Our findings provide a po-
tential role for visfatin in the pathogenesis of endothelial dys-
function and a variety of vascular inflammatory disorders. This
knowledge may contribute to the development of new therapies
for obesity-related vascular diseases.Acknowledgements
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